Growth Drivers and Chain of Events Leading to the Strategic Advantage
- 15 Biologics Going Off Patent (2025–2029)
One of the key biologics which has been declared as a product of interest for achieving future growth initiatives according to the Biocon Biologics Q3 (Financial Year 26) revenue report.
- Biocon Biologics has taken strategic actions to strengthen its biologics portfolio, accelerate market access, and enhance commercial flexibility, supporting long-term growth.
Biocon Biologics has disclosed three new biosimilars assets in its pipeline – Trastuzumab subcutaneous (SC), Nivolumab, and Pembrolizumab. These are among the largest oncology biologics scheduled to lose exclusivity over the next five years
According to press announcements in key newspapers in the first two weeks of February 2026, a business forum was organized by industry lobby body FICCI in partnership with the Department for Promotion of Industry and Internal Trade (DPIIT) and Brazilian trade authorities to scale up economic engagement.
- As a part of the bilateral talks between India and Brazil, efforts to boost trade and exports in the area of the pharmaceuticals, the following 2 key agreements were signed: in pharmaceuticals resulted in the following key agreements:
- In pharmaceuticals, Farmanguinhos / Fiocruz and Biocon Pharma signed an MoU for joint research and development in strategic medicines, including oncology and rare diseases, aimed at public health systems.
- Separately, BahiaFarma, Biocon Biologics and Bionovis entered into a commitment agreement for the productive development of Pertuzumab, a HER-2 metastatic breast cancer treatment, covering an estimated 72,000 patients annually at a procurement value of BRL 503.4 million.
According to the ministry of Commerce & Industry, trade between the two countries stood at $2.4 billion in 2006, risen to nearly $13 billion in 2025 which could reach $30 billion by 2030, doubling from current levels. India Biopharma could act as a key contributor of this growth in the coming decade.
Sources:
https://clival.com/blog/15-biologics-are-going-off-patent-2025-to-2029